Leah S. Millheiser, M.D.
A Twelve Month, Open-Label, Safety Trial of Flibanserin 50 Milligrams to 100 Milligrams Daily in Women with Hypoactive Sexual Desire Disorder
Contact Information
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Brief
The purpose of this study is to find out if the investigational drug, flibanserin, is safe and effective for the treatment of women with HSDD.
Recruiting Status:
RecruitingStanford Recruiting Status:
RecruitingCondition(s):
Intervention(s):
- Drug: flibanserin
Phase:
Phase 3Eligibility
Ages Eligible for Study:
18 years to Any AgeGenders Eligible for Study:
FemaleHealth of Volunteers:
People with the conditions listed in this trial can participate as controls.Key Inclusion Criteria:
Premenopausal women with a primary diagnosis of HSDD who have completed participation in a prior study of flibanserin
Key Exclusion Criteria:
You may not participate unless you have completed participation in a prior study of flibanserin
Additional Study Details
Official Title:
A Twelve Month, Open-Label, Safety Trial of Flibanserin 50 Milligrams to 100 Milligrams Daily in Women with Hypoactive Sexual Desire DisorderAnticipated start date:
10/9/2007Lead Sponsor:
Boehringer Ingelheim Pharmaceuticals, Inc.Investigator(s):
Study Type:
InterventionalPurpose:
TreatmentAllocation:
Non-randomizedMasking:
OpenControl:
noneAssignment:
Single GroupEndpoints:
SafetyPrimary Outcomes:
- Assessment of adverse events related to drug
Total Number to be Enrolled:
2000Total Number to be Enrolled at Stanford:
10More Information
Secondary ID(s):
- 9100
Locations & Contacts
Stanford Locations & Contacts:
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Non-Stanford Locations:
The Stanford website does not have any locations outside of Stanford listed for this trial. You may want to check clinicaltrials.gov for posible additional locations.
This listing was last updated:
11/10/2007PLEASE NOTE:
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician please feel free to call the SHC Physician Referral Service at (800) 756-9000 or send an email.
Help